Compare MSEX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSEX | CRVS |
|---|---|---|
| Founded | 1897 | 2014 |
| Country | United States | United States |
| Employees | 395 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 984.5M | 1.1B |
| IPO Year | N/A | 2016 |
| Metric | MSEX | CRVS |
|---|---|---|
| Price | $57.66 | $14.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $61.33 | $30.17 |
| AVG Volume (30 Days) | 153.9K | ★ 1.3M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.60 | N/A |
| Revenue Next Year | $10.94 | N/A |
| P/E Ratio | $22.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.94 | $3.79 |
| 52 Week High | $62.18 | $26.95 |
| Indicator | MSEX | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 73.53 | 69.99 |
| Support Level | $49.91 | $14.24 |
| Resistance Level | $62.18 | $16.85 |
| Average True Range (ATR) | 1.20 | 0.79 |
| MACD | 0.47 | 0.43 |
| Stochastic Oscillator | 93.28 | 79.70 |
Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.